1. Tiegs G, Lohse AW (2010): Immune tolerance: what is unique about the liver. J Autoimmun 34:1-6.
2.
Greten TF, Sangro B (2017): Targets for immunotherapy of liver cancer. J Hepatol S0168-8278(17)32287-0.
3.
Zhou G, Sprengers D, Boor PPC, et al. (2017): Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology 153: 1107-1119.
4.
Reig M, Forner A, Rimola J, et al. (2022): BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76: 681-693.
5.
Zhuo N, Liu C, Zhang Q, et al. (2022): Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer. JAMA Netw Open 5: e224637.
6.
Mocan T, Sparchez Z, Craciun R et al. (2019): Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 21: 702-712.
7.
Zhao Y, Li H, Bai W, et al. (2016): Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients. Int J Cancer 139: 928-937.
8.
Zhao S, Zhang T, Dou W, et al. (2020): A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis. Ann Transl Med 8: 542.
9.
Zhu Y, Sun PH, Wang KY, et al. (2021): Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell Int 21: 503.
10.
Qin J, Huang YS, Zhou HJ, et al. (2022): Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. Front Oncol 12: 807102.
11.
Heimbach JK, Kulik LM, Finn RS, et al. (2018): AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67: 358-380.
12.
Zhao XH, Yuan H, Xia WL, et al. (2022): Prospective study of TACE combined with sorafenib vs TACE combined with (125)I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas. Front Oncol 12: 977462.
13.
He M, Li Q, Zou R, et al. (2019): Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol 5: 953-960.
14.
Llovet JM, Lencioni R. (2020): mRECIST for HCC: Performance and novel refinements. J Hepatol 72: 288-306.
15.
Cai M, Huang W, Huang J, et al. (2022): Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol 13: 848387.
16.
Gerstberger S, Jiang Q, Ganesh K (2023): Metastasis. Cell 186: 1564-1579.
17.
El-Khoueiry AB, Sangro B, Yau T, et al. (2017): Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389: 2492-2502.
18.
Yau T, Park JW, Finn RS, et al. (2019): CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 30:v874-v875.
19.
Andrew XZ, Richard SF, Julien E, et al. (2018): Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 18: 940-952.
20.
Qin SK, Ren ZG, Meng ZQ, et al. (2020): Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncology 21: 571-580.
21.
Schoenfeld AJ, Hellmann MD (2020): Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37: 443-455.
22.
Xia WL, Zhao XH, Guo Y, et al. (2022): Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study. Front Oncol 12: 961394.
23.
Ke Q, Xin F, Fang H, et al. (2022): The significance of transarterial chemo(embolization) combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma in the era of systemic therapy: a systematic review. Front Immunol 13: 913464.
24.
Lee JC, Mehdizadeh S, Smith J, et al. (2020): Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol 5: eaba0759.
25.
Yu J, Green MD, Li S, et al. (2021): Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med 27: 152-164.
26.
Waki K , Yamada T , Yoshiyama K , et al. (2014): PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Science 105: 1229.
27.
Ottonello S, Genova C, Cossu I, et al. (2020): Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer. Front Immunol 11: 125.
28.
Huo TI, Lin HC (2008): Metastatic hepatocellular carcinoma: when, how, where and so what? Liver Int 28: 1183-1185.
29.
Yoo SW, Kim DY, Pyo A, et al. (2021): Differences in diagnostic impact of dual-tracer PET/computed tomography according to the extrahepatic metastatic site in patients with hepatocellular carcinoma. Nucl Med Commun 42: 685-693.
30.
Ielasi L, Tovoli F, Tonnini M, et al. (2023): Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma. Cancers (Basel) 15: 1523.
